A PYMNTS Company

US: Celgene exclusive dealing suit to proceed

By  |  January 14, 2015

Mylen Pharmaceuticals received permission from a federal district court in New Jersey to continue its antitrust lawsuit against Celgene Corporation.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The court found that there are sufficient facts for Mylen to plead an antitrust claim under Section 2 of the Sherman Act. Section 2 deals with end results that are anticompetitive, whereas Section 1 specifies and prohibits anti-competitive behavior. Mylen alleges that Celgene refused a generic rival access to samples of its branded drugs.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    This case is one of few to deal with Section 2 in application to companies refusing to deal with a rival and, as such, is expected to be instructive.

    Full Content: Health Law & Policy Matters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.